this May. “And so, we're trying to automate out some of the steps that might lead to bottlenecks and longer timelines in both construct design for manufacturing and data analysis.”
“The way that we like to think about Form Bio is that it's a platform to enable synthetic biology,” explains Stearn. “Typical synbio organizations have heavy R&D investment on the science side of things, but the data science side might be under-resourced. Our platform is a one-stop shop for all things data management, visualization, analysis, workflows, and collaboration.”
이 소식을 빠르게 읽을 수 있도록 요약했습니다. 뉴스에 관심이 있으시면 여기에서 전문을 읽으실 수 있습니다. 더 많은 것을 읽으십시오: